ECSP14002458A - Inhibidor de cetp de oxazolidona biciclico fusionado - Google Patents

Inhibidor de cetp de oxazolidona biciclico fusionado

Info

Publication number
ECSP14002458A
ECSP14002458A ECIEPI20142458A ECPI201402458A ECSP14002458A EC SP14002458 A ECSP14002458 A EC SP14002458A EC IEPI20142458 A ECIEPI20142458 A EC IEPI20142458A EC PI201402458 A ECPI201402458 A EC PI201402458A EC SP14002458 A ECSP14002458 A EC SP14002458A
Authority
EC
Ecuador
Prior art keywords
oxazolidone
fused bicyclic
cetp inhibitor
compounds
cetp
Prior art date
Application number
ECIEPI20142458A
Other languages
English (en)
Spanish (es)
Inventor
Deyou Sha
Pengcheng Patrick Shao
Feng Ye
Petr Vachal
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP14002458A publication Critical patent/ECSP14002458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ECIEPI20142458A 2011-10-28 2014-05-28 Inhibidor de cetp de oxazolidona biciclico fusionado ECSP14002458A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552592P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
ECSP14002458A true ECSP14002458A (es) 2015-11-30

Family

ID=47143312

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20142458A ECSP14002458A (es) 2011-10-28 2014-05-28 Inhibidor de cetp de oxazolidona biciclico fusionado

Country Status (41)

Country Link
US (2) US8871738B2 (cg-RX-API-DMAC7.html)
EP (1) EP2771345B1 (cg-RX-API-DMAC7.html)
JP (1) JP5658427B2 (cg-RX-API-DMAC7.html)
KR (1) KR101686308B1 (cg-RX-API-DMAC7.html)
CN (1) CN103958524B (cg-RX-API-DMAC7.html)
AR (1) AR088565A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012328759B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010204A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852743C (cg-RX-API-DMAC7.html)
CL (1) CL2014001090A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940419A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140256A (cg-RX-API-DMAC7.html)
CY (1) CY1118464T1 (cg-RX-API-DMAC7.html)
DK (1) DK2771345T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000086A (cg-RX-API-DMAC7.html)
EA (1) EA026123B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14002458A (cg-RX-API-DMAC7.html)
ES (1) ES2604953T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166434B (cg-RX-API-DMAC7.html)
HR (1) HRP20161541T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030568T2 (cg-RX-API-DMAC7.html)
IL (1) IL232130A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03073A (cg-RX-API-DMAC7.html)
JO (1) JO3210B1 (cg-RX-API-DMAC7.html)
LT (1) LT2771345T (cg-RX-API-DMAC7.html)
MA (1) MA35643B1 (cg-RX-API-DMAC7.html)
ME (1) ME02557B (cg-RX-API-DMAC7.html)
MX (1) MX345222B (cg-RX-API-DMAC7.html)
NI (1) NI201400034A (cg-RX-API-DMAC7.html)
PE (1) PE20141230A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500890A1 (cg-RX-API-DMAC7.html)
PL (1) PL2771345T3 (cg-RX-API-DMAC7.html)
PT (1) PT2771345T (cg-RX-API-DMAC7.html)
RS (1) RS55420B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401884PA (cg-RX-API-DMAC7.html)
SI (1) SI2771345T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000158A1 (cg-RX-API-DMAC7.html)
TW (1) TWI601731B (cg-RX-API-DMAC7.html)
UA (1) UA114612C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013063217A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201403091B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
JP5852662B2 (ja) 2010-10-29 2016-02-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 環状アミン置換されたオキサゾリジノン系ｃｅｔｐ阻害薬
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2934518B1 (en) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
US9376408B2 (en) 2012-12-20 2016-06-28 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
DK2943474T3 (en) * 2013-01-31 2017-08-21 Chong Kun Dang Pharmaceutical Corp BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXE DERIVATE COMPOUNDS AS CETP INHIBITORS
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3027619B1 (en) * 2013-07-30 2019-01-02 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
WO2015031228A1 (en) * 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
US9663534B2 (en) 2013-12-17 2017-05-30 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
UA120922C2 (uk) 2014-02-05 2020-03-10 Дезима Фарма Б.В. Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HRP20210338T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije fgfr-i cmet-inhibitora za liječenje raka
CN106456648B (zh) 2014-03-26 2021-11-02 阿斯特克斯治疗有限公司 Fgfr抑制剂和igf1r抑制剂的组合
US10011572B2 (en) 2014-07-29 2018-07-03 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016067194A1 (en) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Process for the preparation of anacetrapib and an intermediate thereof
US20170252338A1 (en) * 2014-11-28 2017-09-07 Kowa Company, Ltd. Medicine
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN109996757A (zh) * 2015-06-12 2019-07-09 罗地亚经营管理公司 含枝状体的混合纳米粒子、生产此类混合纳米粒子的方法以及它们的用途
US20180230166A1 (en) * 2015-07-13 2018-08-16 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
LT3353164T (lt) 2015-09-23 2022-01-25 Janssen Pharmaceutica, N.V. Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui
AU2016328692B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv New compounds
CN106432053A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法
CN106432058A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种Niraparib中间体4‑（3S‑哌啶‑3‑基）苯胺的制备方法
CN111285894B (zh) * 2018-12-10 2021-03-05 北京天一绿甫医药科技有限公司 用于制备软海绵素类化合物的中间体及其制备方法
CN110639018B (zh) * 2019-11-14 2020-06-26 牡丹江医学院 一种防治老年性高血压的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc INDOLES HAVING ANTIDIABETIC EFFECT
PT1537078E (pt) 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
CN100403900C (zh) * 2003-06-12 2008-07-23 麦克公司 有丝分裂驱动蛋白抑制剂
US7307085B2 (en) 2003-08-13 2007-12-11 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1938320A (zh) * 2004-03-26 2007-03-28 伊莱利利公司 用于治疗异常脂肪血症的化合物和方法
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US7888369B2 (en) 2005-12-22 2011-02-15 Schering Corporation Oxazoloisoquinoline derivatives as thrombin receptor antagonists
US7910592B2 (en) 2005-12-30 2011-03-22 Merck Sharp & Dohme Corp. CETP inhibitors
AU2006335110B2 (en) 2005-12-30 2011-04-14 Merck Sharp & Dohme Corp. CETP inhibitors
EP2029560B1 (en) 2005-12-30 2013-04-24 Merck Sharp & Dohme Corp. 1,3-oxazolidin-2-one derivatives useeful as cetp inhibitors
EP2348859B1 (en) 2008-10-01 2013-12-04 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone cetp inhibitors
WO2011028395A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Pyridyl oxazolidinone cetp inhibitor
JP5852662B2 (ja) 2010-10-29 2016-02-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 環状アミン置換されたオキサゾリジノン系ｃｅｔｐ阻害薬
US9353101B2 (en) 2012-05-02 2016-05-31 Merck Sharp & Dohme Corp. Cyclic amine substituted heterocyclic CETP inhibitors

Also Published As

Publication number Publication date
PH12014500890A1 (en) 2014-06-09
PE20141230A1 (es) 2014-09-28
US9346825B2 (en) 2016-05-24
CN103958524A (zh) 2014-07-30
MX345222B (es) 2017-01-20
NI201400034A (es) 2014-10-10
US20140378493A1 (en) 2014-12-25
LT2771345T (lt) 2016-11-25
AU2012328759A1 (en) 2014-05-01
GEP20166434B (en) 2016-02-10
TW201321388A (zh) 2013-06-01
JP2014532652A (ja) 2014-12-08
AR088565A1 (es) 2014-06-18
ES2604953T3 (es) 2017-03-10
PL2771345T3 (pl) 2017-04-28
RS55420B1 (sr) 2017-04-28
IN2014CN03073A (cg-RX-API-DMAC7.html) 2015-07-31
ME02557B (me) 2017-02-20
EP2771345B1 (en) 2016-09-21
DK2771345T3 (en) 2017-01-09
ZA201406833B (en) 2016-02-24
HRP20161541T1 (hr) 2016-12-30
MX2014005074A (es) 2014-08-01
NZ625435A (en) 2015-12-24
SG11201401884PA (en) 2014-09-26
TN2014000158A1 (en) 2015-09-30
PT2771345T (pt) 2016-11-30
DOP2014000086A (es) 2014-07-15
AU2012328759B2 (en) 2015-09-10
CA2852743A1 (en) 2013-05-02
EA026123B1 (ru) 2017-03-31
CR20140256A (es) 2014-07-15
EA201490889A1 (ru) 2015-05-29
US20130109649A1 (en) 2013-05-02
UA114612C2 (uk) 2017-07-10
ZA201403091B (en) 2015-04-29
KR101686308B1 (ko) 2016-12-13
BR112014010204A2 (pt) 2017-05-09
CN103958524B (zh) 2016-04-06
IL232130A0 (en) 2014-05-28
CO6940419A2 (es) 2014-05-09
US8871738B2 (en) 2014-10-28
KR20140094571A (ko) 2014-07-30
IL232130A (en) 2017-07-31
MA35643B1 (fr) 2014-11-01
CL2014001090A1 (es) 2014-08-01
WO2013063217A1 (en) 2013-05-02
SI2771345T1 (sl) 2016-12-30
EP2771345A1 (en) 2014-09-03
CA2852743C (en) 2016-08-02
HUE030568T2 (en) 2017-05-29
CY1118464T1 (el) 2017-07-12
TWI601731B (zh) 2017-10-11
JO3210B1 (ar) 2018-03-08
HK1195558A1 (zh) 2014-11-14
JP5658427B2 (ja) 2015-01-28

Similar Documents

Publication Publication Date Title
ECSP14002458A (es) Inhibidor de cetp de oxazolidona biciclico fusionado
UY39630A (es) Inhibidores de bromodominios
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CR20120418A (es) Inhibidores de virus flaviviridae
MX2020005498A (es) Inhibidores de cdk.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
ECSP12012104A (es) Inhibidores de virus flaviviridae
NI201500032A (es) Métodos para el tratamiento de cáncer de mamas localmente avanzado
MX2015008052A (es) Inhibidores de prmt5 y sus usos.
CO7030960A2 (es) Inhibidores de pak para el tratamiento de los trastornos de proliferación celular
CR20140151A (es) Compuestos de piperidina útiles para el tratamiento de enfermedades neurodegenerativas-1-arilcarbolino-4-oxya
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX2016002178A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
CR20150061A (es) Compuesto de pirazolopirimidinas
CO6910192A2 (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de pi3kbeta y el inhibidor de la vía de map, incluídos los inhibidores de mek y raf
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia